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Abstract: Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet)
and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular
drug use. We studied the association between cumulative average of MedDiet adherence and
LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk
(PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering
drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets
(n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides
(n = 6954). One-point increases in MedDiet adherence were linearly associated with a decreased
initiation of glucose-lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin
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(HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K
antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy
(HR: 0.69 [0.56–0.84]). LTPA was non-linearly related to a delayed initiation of glucose-lowering,
antihypertensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum
risk: 180–360 metabolic equivalents of task-min/day). Both combined were synergistically associated
with a decreased onset of glucose-lowering drugs (p-interaction = 0.04), antihypertensive drugs (p-
interaction < 0.001), vitamin K antagonists (p-interaction = 0.04), and cardiac glycosides (p-interaction
= 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk
of initiating cardiovascular-related medications.
Keywords: mediterranean diet; physical activity; glucose-lowering drugs; antihypertensive drugs;
statins; fibrates; antiplatelet drugs; vitamin K epoxide reductase inhibitors; antianginal drugs;
cardiac glycosides
1. Introduction
Better adherence to a Mediterranean Diet (MedDiet) and regular practice of leisure-
time physical activity (LTPA) are both able to prevent major cardiovascular clinical out-
comes [1,2]. Beneficial effects of MedDiet and LTPA may be mediated by improvements
in risk factors related to blood pressure, glucose and lipid metabolism, oxidative stress,
and low-grade inflammation [3,4]. However, there is limited information on the effect of
lifestyle factors on the need of or delay in cardiovascular drug use. Regarding dietary
modifications, only two studies are available and focused on antidiabetic therapy. A
MedDiet intervention was associated with a decreased risk of initiating glucose-lowering
therapy in non-treated type 2 diabetes patients in the PREDIMED (PREvención con DIeta
MEDiterránea) study [5], and another intervention with a low-carbohydrate MedDiet-
like dietary pattern was related to a reduced need of these medications in middle-aged
adults [6]. In relation to physical activity, beyond the association between LTPA and a
greater discontinuation of antidiabetic treatment [7] or a reduced risk of warfarin bleeding
complications [8], only one cohort study in a Scandinavian general population has re-
ported that higher LTPA levels are linked to a decreased risk of initiating antihypertensive
medication [9].
High adherence to a MedDiet together with high LTPA levels has been associated
with a decreased risk of cardiovascular events [10] and all-cause mortality [11]. Short-term,
small-scale intervention studies recommending a combination of a MedDiet-like dietary
pattern and LTPA have been related to decreases in body weight, blood pressure, fasting
glucose, insulin resistance, total cholesterol, and triglyceride levels [12]. In addition, interim
analyses of the first year of a large-scale intervention with a combination of hypocaloric
MedDiet with LTPA and behavioral support in the PREDIMED-Plus study have confirmed
these benefits and reported a decrease in the levels of leptin and low-grade inflammation
biomarkers [13]. However, the combined effect of MedDiet and LTPA on the necessity of
cardiovascular drugs, and a potential synergistic protection, is still unknown. Therefore,
the aim of this study was to assess the prospective association of high adherence to a
MedDiet and LTPA levels, alone and combined, with the risk of initiating cardiovascular
drug use in Spanish older adults at high cardiovascular risk.
2. Materials and Methods
2.1. Study Population
This work is a prospective analysis using information about participants of the PRED-
IMED trial as a cohort study. The PREDIMED trial was a randomized controlled trial
conducted in Spain between 2003 and 2009 to assess the effects of a nutritional interven-
tion fostering the adherence to a MedDiet on the primary prevention of cardiovascular
outcomes in an older population at high cardiovascular risk. Eligible volunteers were
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men (aged 55–80 years) and women (aged 60–80 years) without cardiovascular disease
at enrolment but with type 2 diabetes or at least three of the following cardiovascular
risk factors: hypertension (systolic blood pressure ≥ 140 mmHg, diastolic blood pres-
sure ≥ 90 mmHg, or using antihypertensive drugs), high concentrations of low-density
lipoprotein cholesterol (≥160 mg/dL), low levels of high-density lipoprotein cholesterol
(<40 mg/dL in men, <50 mg/dL in women), body mass index > 25 kg/m2, smoking, and
family history of premature coronary disease (<55 years old in first degree male relatives,
<65 years old in first degree female relatives). The study protocol complied with the Dec-
laration of Helsinki, was approved by Institutional Review Boards of all recruiting sites,
was registered under the International Standard Randomized Controlled Trial Number IS-
RCTN35739639 (http://www.isrctn.com/ISRCTN35739639, accessed on 28 January 2021),
has been previously described in detail elsewhere [1,14], and is available in the PREDIMED
study website (http://www.predimed.es, accessed on 28 January 2021). All participants
provided written informed consent before joining the trial.
For these analyses, we used the PREDIMED data as an observational prospective
cohort, adjusting all analyses for intervention groups. Of the 7447 randomized participants,
we excluded 87 with no available baseline data on MedDiet adherence, alcohol intake, or
energy consumption, and 297 without information on cardiovascular drug use at follow-up
visits, yielding an analytical sample of 7063 individuals. Of note, analyses of initiation
of cardiovascular-related drugs were performed in non-users at study entry, so we also
excluded users of each specific drug at baseline. Furthermore, we excluded volunteers
with no information on baseline levels of fasting glucose (n = 313), systolic blood pressure
(n = 9), total cholesterol (n = 221), and triglycerides (n = 344) in the analyses related to the
initiation of glucose-lowering drugs, antihypertensive medication, statins, and fibrates,
respectively. The study flowchart is available in Figure 1.
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2.2. Outcomes
At baseline and yearly follow-up visits, we collected data on the use (yes/no) of the
main cardiovascular-related drugs. Glucose-lowering drugs included biguanides, thia-
zolidinediones, sulfonylureas, meglitinides, glucagon-like peptide analogues/agonists,
dipeptidyl peptidase-4 inhibitors, α-glycosidase inhibitors, and insulin. Antihyperten-
sive therapies included renin-angiotensin-aldosterone system inhibitors, calcium antago-
nists, thiazide/thiazide-like/loop diuretics, mineralocorticoid receptor antagonists, beta-
blockers, alpha-blockers, and other minor antihypertensive families. Lipid-lowering drug
use was defined as any use of statins or fibrates. Antiplatelet drugs included acetylsalicylic
acid as antiplatelet, cilostazol, clopidogrel, dipyridamole, ditazol, ticlopidine, and triflusal.
When assessing the use of other anticoagulants, we registered any use of vitamin K epoxide
reductase inhibitors (warfarin and acenocumarol) (the use of other anticoagulants, such as
direct oral anticoagulant drugs, was marginal in the follow-up period of our study). An-
tianginal drugs included nitrates (nitroglycerin, isosorbide mononitrate, molsidomine) and
other angina pectoris drugs (trimetazidine, ivabradine, ranolazine). Finally, we registered
any use of cardiac glycosides.
Using these data, we defined incidence of the initiation of any of these therapies
among baseline non-users. “Initiation” was defined as the occurrence of the initiation of
medication use that lasted until the last visit of the volunteer [5]. Regarding doubtful cases,
we only considered as valid outcomes any initiation of medication that persisted for at
least three subsequent follow-up visits and was not based on more than one visit in which
the use of the drug was not reported.
2.3. Exposure Variables
We estimated MedDiet adherence at each visit using the MedDiet adherence score. It
was a short screener questioning whether the volunteer followed 14 essential dietary traits
related to a MedDiet, validated in Spanish adults. The consumption of the following scored
positively: (1) olive oil as main fat for cooking/seasoning; (2) ≥4 tablespoons/day of olive
oil; (3) ≥2 servings/day of vegetables; (4) ≥3 servings/day of fruit; (5) ≥3 servings of
mixed nuts (30 g) per week; (6) ≥3 servings of legumes (150 g, boiled) per week; (7) ≥3 serv-
ings/week of fish or seafood; (8) wine in moderation (100 mL/day on average, within
meals); (9) <1 serving/day of red and processed meat; (10) poultry and rabbit over red and
processed meat; (11) <1 serving/day of butter, margarine, or cream; (12) <1 carbonated
or sugar-sweetened beverage/day; (13) <2 servings/week of non-homemade pastries or
sweets; and (14) a “sofrito”-based dish at least twice per week [15].
LTPA was estimated by the self-administered Minnesota Leisure-Time Physical Activ-
ity Questionnaire, previously validated in Spanish men and women [16,17]. The question-
naire reported the number of days and min/day that participants performed 67 different
activities in the previous year. LTPA was quantified in metabolic equivalents of task-minute
per day (METs-min/d) by multiplying the metabolic equivalents of task linked to an activity
with its mean duration in min/day.
2.4. Covariates
Trained personnel collected baseline data on: age; sex; educational level; prevalence
of diabetes, hypercholesterolemia, hypertriglyceridemia, and hypertension; systolic blood
pressure; body mass index; and smoking habit [1,14]. Glucose, total cholesterol, and
triglyceride levels were assessed in local laboratories in overnight fasting plasma samples
collected at baseline and stored at −80 ◦C until analysis. From a validated 137-item food
frequency questionnaire, we estimated the consumption of alcohol (in g/day) and energy
(in kcal/day) [14].
2.5. Power Analyses
The number of total individuals and cases that occurred during follow-up allowed to
detect as significant (α = 0.05), with a power ≥80%, hazard ratios (HR) for the comparisons
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between low MedDiet adherence + low LTPA levels and high MedDiet adherence + high
LTPA levels ranging from 0.38 (cardiac glycoside) to 0.80 (statin) (Table S1). This calculation
was performed using the “powerSurvEpi” package in R Software [18].
2.6. Statistical Analyses
Baseline characteristics were expressed as means and standard deviations (normally
distributed continuous variables), medians and interquartile ranges (non-normally dis-
tributed continuous variables), and proportions (categorical variables).
We used Cox proportional hazards regression models with restricted cubic splines
to evaluate graphically the non-linear associations of the cumulative mean of MedDiet
adherence and of LTPA levels with the risk of starting to use cardiovascular-related med-
ications [19]. We calculated the cumulative mean of MedDiet adherence or LTPA as the
average of all adherence score/LTPA values until the occurrence of the outcome (incident
cases) or the last study visit with available data (non-cases). Any participant with out-
lier values in cumulative means of MedDiet adherence score (<5 points) or LTPA levels
(>1000 METs-min/day) was excluded. We set the reference cut-point at the minimum
value for each exposure variable (5 points of MedDiet adherence score, 0 METs-min/day
of LTPA). We defined follow-up time as the time between the date of enrolment and:
(1) the midpoint between the last visit in which the volunteer did not use the medica-
tion and the first visit in which the volunteer reported its use; or (2) 1 December 2010,
whichever came first. Models were stratified by sex, recruitment site, and educational level
(primary/secondary/higher/unavailable), and adjusted for baseline: age (continuous),
diabetes (yes/no), hypercholesterolemia (yes/no), hypertriglyceridemia (yes/no), hyper-
tension (yes/no), smoking habit (current/former/never), body mass index (continuous),
alcohol consumption (continuous), energy intake (continuous), and PREDIMED interven-
tion group. MedDiet adherence analyses were further adjusted for LTPA (continuous), and
LTPA analyses for MedDiet adherence score (continuous). We substituted the following
covariates in the models: diabetes for fasting glucose (continuous) in glucose-lowering
therapy initiation analyses, hypertension for systolic blood pressure in antihypertensive
therapy initiation analyses, hypercholesterolemia for total cholesterol (continuous) in statin
initiation analyses, and hypertriglyceridemia for triglycerides (continuous) in fibrate initia-
tion analyses. We used robust variance estimators to account for intra-cluster correlations
in all survival analyses [1].
To study the combined effect of diet and physical activity, we first classified vol-
unteers according to their cumulative means of MedDiet adherence and LTPA values
(“low”—below the media—or “high”—above the median—values). We then classified
the participants in four categories: low values in both exposures (reference), low MedDiet
adherence and high LTPA, high MedDiet adherence and low LTPA, and high MedDiet ad-
herence and LTPA. We tested whether high MedDiet adherence and high LTPA levels were
synergistically associated with lower risk of drug initiation by applying a likelihood ratio
test between the Cox models with and without the interaction product-term “cumulative
MedDiet adherence x cumulative LTPA.”




Study volunteers were elderly adults (67 years old on average, 58% women) with
high prevalence of cardiovascular risk factors at baseline (83% hypertension, 72% hyperc-
holesterolemia, 49% diabetes, 47% obesity, 14% current smokers) (Table 1). The number
of persons at risk of new drug use and median follow-up times were as follows for each
drug-specific analysis: glucose-lowering drugs (n = 4437, 4.0 years), antihypertensive drugs
(n = 2145, 2.6 years), statins (n = 3977, 3.7 years), fibrates (n = 6391, 4.8 years), antiplatelet
drugs (n = 5760, 4.0 years), vitamin K epoxide reductase inhibitors (n = 6877, 4.5 years),
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antianginal drugs (n = 6837, 4.6 years), and cardiac glycosides (n = 6954, 4.8 years). Among
the individuals susceptible to initiate medication, the use of antidiabetics was initiated
in 16.9% of the participants, antihypertensive drugs in 46.2%, statins in 30.0%, fibrates
in 2.16%, antiplatelet drugs in 19.1%, vitamin K epoxide reductase inhibitors in 3.00%,
antianginal drugs in 2.47%, and cardiac glycosides in 0.82%.
Table 1. Study population 1.
Main Analytical Sample (n = 7063)
Age (years), mean ± SD 67.0 ± 6.2
Female sex, n (%) 4080 (57.8)
Diabetes, n (%) 3442 (48.7)
Hypercholesterolemia, n (%) 5087 (72.0)
Hypertriglyceridemia, n (%) 2045 (29.0)
Hypertension, n (%) 5834 (82.6)
Smoking habit:
Never smokers, n (%) 4345 (61.5)
Current smokers, n (%) 985 (13.9)
Former smokers, n (%) 1733 (24.5)
Weight status (according to body mass index):
18.5–24.9 kg/m2, n (%) 523 (7.40)
25.0–29.9 kg/m2, n (%) 3207 (45.4)
≥30 kg/m2, n (%) 3333 (47.2)
PREDIMED Study intervention groups:
MedDiet enriched with extra-virgin olive oil, n (%) 2465 (34.9)
MedDiet enriched with mixed nuts, n (%) 2308 (32.7)
Control group, n (%) 2290 (32.4)
MedDiet adherence score, mean ± SD 8.69 ± 1.90
Leisure-time physical activity (metabolic equivalents of
task-min/day), median (1st–3rd quartile) 175 (66.1–319)
Alcohol intake (g/day), median (1st–3rd quartile) 1.49 (0.00–10.4)
Energy intake (kcal/day), mean ± SD 2274 ± 604
Carbohydrates (g/day), median (1st–3rd quartile) 227 (182–279)
Protein (g/day), median (1st–3rd quartile) 90.2 (77.0–106)
Total fat (g/day), median (1st–3rd quartile) 96.4 (77.5–116)
Saturated fat (g/day), median (1st–3rd quartile) 24.1 (19.1–30.1)
Monounsaturated fat (g/day), median (1st–3rd quartile) 48.5 (36.4–58.9)
Polyunsaturated fat (g/day), median (1st–3rd quartile) 14.4 (11.0–19.3)
Omega-3 polyunsaturated fat (g/day), median (1st–3rd quartile) 2.04 (1.56–2.68)
Fiber (g/day), median (1st–3rd quartile) 24.0 (19.4–29.9)
Dietary cholesterol (mg/day), median (1st–3rd quartile) 357 (284–429)
Sodium (mg/day), median (1st–3rd quartile) 2263 (1767–2877)
Potassium (mg/day), median (1st–3rd quartile) 4195 (3586–4940)
Calcium (mg/day), median (1st–3rd quartile) 993 (779–1274)
Dietary vitamin D (µg/day), median (1st–3rd quartile) 4.77 (3.33–8.61)
Vitamin C (mg/day), median (1st–3rd quartile) 184 (139–245)
Vitamin E (mg/day), median (1st–3rd quartile) 9.31 (7.57–11.7)
1 MedDiet: Mediterranean diet; PREDIMED: PREvención con DIeta MEDiterránea.
3.2. MedDiet Adherence and Risk of Cardiovascular Drug Initiation
One-point increases in cumulative MedDiet adherence were linearly associated with
the following decreases in the risk of drug initiation: 24% for glucose-lowering therapy (HR:
0.76 [95% CI: 0.71; 0.80]), 21% for antihypertensive medication, (HR: 0.79 [0.75; 0.82]), 18%
for statins (HR: 0.82 [0.78; 0.85]), 22% for fibrates (HR: 0.78 [0.68; 0.89]), 21% for antiplatelet
drugs (HR: 0.79 [0.75; 0.83]), 17% for vitamin K epoxide reductase inhibitors (HR: 0.83 [0.74;
0.93]), 16% for antianginal drugs (HR: 0.84 [0.74; 0.96]), and 31% for cardiac glycosides (HR:
0.69 [0.56; 0.84]) (Figure 2).
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3.3. LTPA Levels and Risk of Cardiovascular Drug Initiation
LTPA levels were only linearly linked to lower initiation risk of vitamin K epoxide
reductase inhibitors (100 METs-min/day increments were related to 10% less risk, HR:
0.90 [0.81; 1.00]). We observed non-linear associations of LTPA with the risk of initiation
of the rest of cardiovascular drugs (Figure 3). The lowest risk values were observed
between 180 and 360 METs-min/day (relative to 0 METs-min/day) for the following drug
families: glucose-lowering drugs (lowest risk at 198 METs-min/day, HR: 0.44 [0.40; 0.48]),
antihypertensive drugs (at 364 METs-min/day, HR: 0.47 [0.42; 0.52]), statins (at 204 METs-
min/day, HR: 0.51 [0.48; 0.55]), fibrates (at 188 METs-min/day, HR: 0.63 [0.52; 0.77]),
antiplatelet drugs (at 176 METs-min/day, HR: 0.52 [0.49; 0.56]), antianginal drugs (at 202
METs-min/day, HR: 0.53 [0.45; 0.63]), and cardiac glycosides (at 220 METs-min/day (HR:
0.25 [0.18; 0.34]).
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lowering (A), antihypertensive (B), statin (C), fibrate (D), antiplatelet (E), vitamin K epoxide reductase
inhibitors (F), antianginal (G), and cardiac glycoside (H) therapies. Cox proportional hazards regres-
sion models with cubic splines were stratified by sex, recruitment site, and educational level, and
adjusted for: age, diabetes, hypertension, hypercholesterolemia, hypertriglyceridemia, smoking habit,
body mass index, alcohol consumption, energy intake, adherence to a MedDiet, and PREDIMED
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3.4. Adherence to a MedDiet Combined with LTPA Levels and Risk of Cardiovascular Drug
Initiation
High MedDiet adherence and LTPA levels had a synergistic impact on the risk of initiat-
ing the following therapies: glucose-lowering drugs (p-interaction = 0.04), antihypertensive
drugs (p-interaction < 0.001), vitamin K epoxide reductase inhibitors (p-interaction = 0.04),
and cardiac glycosides (p-interaction = 0.01) (Figure 4).
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4. Discussion
In older individuals at high cardiovascular risk, we observed that adherence to a
MedDiet and LTPA of at least approximately 200 METs-min/day were associated with
a decreased necessity of cardiovascular-related medications. In addition, the combina-
tion of MedDiet and LTPA was synergistically associated with a delayed initiation of
glucose-lowering, antihypertensive, vitamin K epoxide reductase inhibitor, and cardiac
glycoside therapies.
Several cardio etabolic benefits of a traditional MedDiet have been described in
observational and clinical studies [3]. Our findings extend this protective association to
cardiovascular-related medications and suggest a delayed initiation of glucose-lowering,
antihypertensive, statin, fibrate, antiplatelet, vitamin K epoxide reductase inhibitor, an-
tianginal, and cardiac glycoside therapies in individuals with high adherence to a MedDiet.
Our results agree with previously reported associations of MedDiet with a decreased
risk of initiating glucose-lowering therapy in type 2 diabetes patients [5] and vitamin K
epoxide reductase inhibitors in high cardiovascular risk individuals [22], reduced blood
pressure values [23], lower total cholesterol and triglyceride concentrations [3], improved
antithrombotic mechanisms [24], and a decreased heart failure risk in cohort studies [25].
MedDiet is known for its richness in antioxidant bioactive compounds, which is thought to
be responsible for the decrease in oxidative stress and low-grade inflammation [26,27]. Its
high content in monounsaturated and polyunsaturated fatty acids may also be involved in
the anti-inflammatory and lipid-lowering effect [28], and its great content in fiber may also
be involved in the improvement of several mechanisms involving gut microbiota [28].
We also observed a non-linear association between LTPA and a decreased necessity of
cardiovascular drugs. With the exception of vitamin K epoxide reductase inhibitors, we
observed the lowest risk of starting to use glucose-lowering, statin, fibrate, antiplatelet,
antianginal, and cardiac glycoside medications around 200 METs-min/day of LTPA (the
maximum decreases in antihypertensive initiation risk were also associated with values
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up to 200 METs-min/day). This is equivalent to 45 min of walking at brisk pace or 30
min of jogging [29]. Meta-analyses of human studies have reported that similar values are
usually the optimum point in the dose-dependent association between LTPA and the risk
of developing a cardiovascular event [2], type 2 diabetes [2], or heart failure [30].
The combination of high LTPA levels and MedDiet adherence was synergistically
associated with a delayed initiation of glucose-lowering, antihypertensive, vitamin K
epoxide reductase inhibitor, and cardiac glycoside therapy. These findings agree with
previous evidence, since the combination of both lifestyle modifications decreases fast-
ing glucose, insulin resistance, blood pressure [12,13], and low-grade inflammation [13]
(which could explain the improvement in thrombosis-related responses, related to vitamin
K antagonist use). The combination of a healthy hypocaloric diet with exercise has also
been additively associated with improvements in heart failure symptoms such as intol-
erance to physical efforts [31]. However, to the best of our knowledge, this is the first
study to report a synergistic association between a healthy, normocaloric diet plus LTPA
and improvements in clinical outcomes related to glucose metabolism, blood pressure,
thrombosis responses, and heart failure. This synergy could be due to the fact that MedDiet
and LTPA enhance these factors through complementary molecular mechanisms. On
the one hand, MedDiet has been shown to be able to improve glucose metabolism [32],
blood pressure [33], atherothrombosis biomarkers [34], and heart failure indicators [35].
These effects may be partially explained by the capacity of its some of MedDiet bioactive
components such as dietary antioxidants to improve oxidative stress and low-grade inflam-
mation [26,27]. Decreases in oxidative stress and low-grade inflammation have been linked
to improvements in the molecular sensitivity of insulin in its target cells [36], increased
endothelial integrity [37], decreased activation of pro-thrombotic signals [38,39], and better
heart dynamics in previous studies [40]. On the other hand, LTPA is known to activate
AMP-activated protein kinase through its capacity to produce transient increases in the
ratio AMP:ATP [41], which in turn may enhance the previous risk factors by alternative
mechanisms. Particularly, it is an enzymatic complex capable of promoting the expres-
sion of several metabolic and regulatory proteins such as enzymes involved in glucose
metabolism, endothelial nitric oxide synthase, antioxidant enzymes, and downregulators
of low-grade inflammation [42,43].
Our study has limitations. First, we conducted our analyses using data of the PRED-
IMED trial, a dietary intervention study that did not include any LTPA advice. Therefore,
we analyzed them as a cohort study, and tried to minimize this limitation by adjusting for
the intervention group and by taking as exposure the cumulative averages of MedDiet
adherence and LTPA levels. Second, our variables can be considered a proxy for the debut
of cardiovascular conditions (a lower initiation of cardiovascular drug use could be due
to the fact that there is less need for medication to control the underlying cardiovascular
risk factors), but we cannot rule out other less obvious reasons for not using medication
(unwillingness/resistance to use pharmacological therapy, etc.). Third, we could only
collect categorical information on drug use/non-use and, consequently, we could not study
dose changes. Fourth, initiation of cardiovascular-related therapy was not a predetermined
endpoint in the PREDIMED study; therefore, our findings should be considered as ex-
ploratory and confirmed in further research. Fifth, our conclusions only apply to older
individuals at high cardiovascular risk and cannot be generalized to other populations.
Finally, some covariates such as alcohol and energy intake are self-reported, which may be
prone to misclassification.
5. Conclusions
In an older population at high cardiovascular risk, adherence to a MedDiet was as-
sociated with lower necessity of cardiovascular-related medications (glucose-lowering,
antihypertensive, statin, fibrate, antiplatelet, vitamin K epoxide reductase inhibitor, an-
tianginal, and cardiac glycoside therapies). LTPA levels were also non-linearly related to
lower drug initiation, with minimum risks observed around 200 METs-min/day. Finally,
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the combination of high MedDiet adherence and LTPA levels was synergistically associated
with a decreased necessity of glucose-lowering, antihypertensive, vitamin K antagonist,
and cardiac glycoside therapies. Our results highlight the potential synergistic associa-
tion between a healthy diet and LTPA with an improvement in cardiovascular health in
individuals at high cardiovascular risk.
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